The global idiopathic pulmonary fibrosis treatment market size is projected to expand at a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increasing prevalence of idiopathic pulmonary fibrosis (IPF) and increasing geriatric population.
Pulmonary fibrosis is a lung condition caused by scarring and damage to lung tissue. It is more difficult for lungs to function efficiently because of this thicker, rigid tissue. As pulmonary fibrosis progresses, patient will become increasingly short of breath. It slows the flow of oxygen from your lungs to your blood, hindering your body from functioning properly. A variety of variables can contribute to the scarring associated with pulmonary fibrosis. Doctors, on the other hand, are often unable to determine what is causing the condition. When the cause of the condition is unknown then it is termed as idiopathic pulmonary fibrosis. Although the lung damage caused by pulmonary fibrosis cannot be cured, but drugs and therapies can assist to reduce the symptoms and improve overall quality of life. A lung transplant may be necessary for some people. Long-term exposure to certain pollutants, certain medical disorders, radiation therapy, and some drugs, among other things, which can cause damage to lung. Long-term exposure to a number of toxins and pollutants such as silica dust, asbestos fiber, hard metal dust, coal dust, grain dust, bird and animal droppings. Some persons who get radiation therapy for lung or breast cancer have lung damage months or years, following the treatment. Lung damage can also result from conditions such as Dermatomyositis, Polymyositis, Mixed connective tissue disease, Systemic lupus erythematosus, Rheumatoid arthritis, Sarcoidosis, Scleroderma, and Pneumonia.
To diagnose the disorder, the doctor may go through the patient's medical and family history, discuss signs and symptoms, discuss any dust, gas, or chemical exposure the patient has had, and perform a physical exam. The doctor may recommend various tests after the physical examination to confirm and determine the severity of the condition. The tests include imaging tests, lung function tests, tissue sample (biopsy), blood tests. The imaging tests includes chest X-ray, computerized tomography (CT) scan, echocardiogram. The lung function tests include pulmonary function testing, pulse oximetry, exercise stress test, and arterial blood gas test. The tissue sample (biopsy) include bronchoscopy and surgical biopsy.
Treatments can help temporarily relieve symptoms or reduce the progression of the condition. Others may be able to assist in improving one's standard of living. The severity of your disorder will be assessed by doctors in order to find the best treatment option for patient. Treatments for pulmonary fibrosis includes oxygen therapy, pulmonary rehabilitation, lung transplant, and medications such as pirfenidone (esbriet) and nintedanib (ofev).
Market Trends, Drivers, Restraints, and Opportunities
- Increasing number of smokers around the world is expected to drive the market growth during the forecast period.
- Growing geriatric population worldwide is anticipated to boost the market growth during the forecast period.
- Increasing health consciousness and proper management strategies for Idiopathic Pulmonary Fibrosis are projected to fuel the market growth during the forecast period.
- Advancements in IPF diagnosis and treatment approaches and introduction of new drugs are factors driving the market growth during the forecast period.
- Increased R&D activities for development of more effective therapies is expected to offer lucrative opportunities for the market players.
Scope of the Report
The report on the global idiopathic pulmonary fibrosis treatment market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Idiopathic Pulmonary Fibrosis Treatment Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Drug Class (MAPK Inhibitors [Esbriets], Tyrosine Inhibitors [Ofev], Autotaxin Inhibitors [GLPG 1690])
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report
F. Hoffman La-Roche Ltd; Boehringer Ingelheim International GmbH; Galapagos; FibroGen, Inc.; Prometic Life Sciences Inc.; Bristol-Myers Squibb Company; MediciNova, Inc.; Merck & Co., Inc.; Novartis AG; and Merck & Co.
Market Segment Insights
MAPK Inhibitors segment is expected to account for a key share of the market
Based on drug class, the idiopathic pulmonary fibrosis treatment market is segmented into MAPK inhibitors, tyrosine inhibitors, and autotaxin inhibitors. The only medications approved by the Food and Drug Administration (FDA) for the treatment of IPF are F. Hoffman La Roche's Esbriet (MAPK Inhibitor) and Boehringer Ingelheim International GmbH's Ofev (Tyrosine Kinase Inhibitor). Both of these medicines help individuals with IPF slow down their functional decline. The MAPK Inhibitors segment is expected to account for a key share of the market during the forecast period owing to its first mover advantage. Due to patients moving from off-label and non-pharmacological therapy, the drug has a well-established safety profile and is likely to achieve a significant market share.
On the other hand, the tyrosine kinase inhibitors (OFEV) segment is anticipated to expand at a rapid pace during the forecast period as FDA identified OFEV as a breakthrough therapy and granted it a fast track, priority review.
North America is anticipated to dominate the market
On the basis of regions, the idiopathic pulmonary fibrosis treatment market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market during the forecast period. The regional market growth can be attributed to high market penetration and increasing prices of the drugs. Moreover, one of the primary factors expected to grow the market is the rising prevalence of IPF. Manufacturers offer a variety of programs to help patients gain access. For example, F. Hoffman La-Roche, Ltd (Genentech) offers the Genentech Access to Care Foundation and Esbriet Co-Pay Card Program, which covers out-of-pocket payments and makes Esbriet available for free to select households with specified income limits. Similar free access and co-pay assistance programs are available from Boehringer Ingelheim.
On the other hand, Europe is expected to exhibit a rapid growth rate in the coming years owing to increased prevalence of IPF. Every year, 30,000 to 35,000 new cases of IPF are detected, according to the European Idiopathic Pulmonary Fibrosis Foundation. Furthermore, IPF affects between 80,000 and 111,000 people in Europe. Patients with IPF generally expect to live for 2 to 5 years on average.
Segments Covered in the Report
The global idiopathic pulmonary fibrosis treatment market has been segmented on the basis of
- MAPK Inhibitors
- Tyrosine Inhibitors
- Autotaxin Inhibitors
- Asia Pacific
- North America
- Latin America
- Middle East & Africa
- F. Hoffman La-Roche Ltd
- Boehringer Ingelheim International GmbH
- FibroGen, Inc.
- Prometic Life Sciences Inc.
- Bristol-Myers Squibb Company
- MediciNova, Inc.
- Merck & Co., Inc.
- Novartis AG
- Merck & Co.
Key players competing in the idiopathic pulmonary fibrosis treatment market are F. Hoffman La-Roche Ltd; Boehringer Ingelheim International GmbH; Galapagos; FibroGen, Inc.; Prometic Life Sciences Inc.; Bristol-Myers Squibb Company; MediciNova, Inc.; Merck & Co., Inc.; Novartis AG; and Merck & Co.
Some of the key business strategies employed by companies includes mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to enhance their market shares.